Press coverage about Biohaven Pharmaceutical (NYSE:BHVN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4323871482025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

Biohaven Pharmaceutical (NYSE:BHVN) opened at $31.24 on Friday. Biohaven Pharmaceutical has a 12-month low of $17.00 and a 12-month high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.03. equities research analysts expect that Biohaven Pharmaceutical will post -6.4 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on BHVN shares. Morgan Stanley raised their target price on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the company an “overweight” rating in a research report on Monday, September 25th. BidaskClub raised shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 28th. Needham & Company LLC decreased their target price on shares of Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday, October 3rd. William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $36.14.

In other Biohaven Pharmaceutical news, major shareholder Portage Biotech Inc. sold 84,881 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.06, for a total value of $2,551,522.86. Following the completion of the sale, the insider now owns 6,278,504 shares in the company, valued at $188,731,830.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Declan Doogan sold 121,942 shares of the stock in a transaction on Friday, January 12th. The shares were sold at an average price of $26.78, for a total transaction of $3,265,606.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,077,450 shares of company stock valued at $29,516,038.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Biohaven Pharmaceutical (BHVN) Stock Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/21/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-biohaven-pharmaceutical-bhvn-stock-price.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.